Positive data on depression treatment based on a drug related to the psychedelic DMT is breathing life into shares of ...

Life Sciences & Beckley Psytech announce positive results from phase 2b study of BPL-003 in patients with treatment-resistant depression: New York Wednesday, July 2, 2025, 10 ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

Cosmo Feilding Mellen – currently Beckley's chief executive, who is slated to serve as chief strategy officer of the merged ...

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

Atai Life Sciences’ psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the next stage of the biotech’s planned merger with mental health company ...

Bay Psychiatric Associates is excited to announce a successful Open House event at its newly expanded San Mateo location, ...

A drug used for Parkinson's disease has been shown to be effective in reducing the symptoms of difficult to treat depression, ...

NRx Pharmaceuticals (NASDAQ: NRXP) , via its wholly owned subsidiary HOPE Therapeutics(TM), Inc., has signed a binding Letter of Intent to acquire a ...

NRx Pharmaceuticals (NASDAQ: NRXP), via its wholly owned subsidiary HOPE Therapeutics (TM), Inc., has signed a binding Letter ...